Investigational immunotherapy
LBA38
Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types
P. Bono, et al.
Conclusions
This phase I/II study with Bexmarilimab in patients with advanced solid tumours demonstrates good initial safety and tolerability, and promising anti-tumour activity as a monotherapy in several refractory metastatic solid tumours. Further expansion of the study will investigate optimal dosing, biomarkers of efficacy and Bexmarilimab’s potential for combination with earlier lines of therapy.
957O
Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-_ and PD-L1
J. Strauss, et al.
Conclusions
Bintrafusp alfa showed long-term efficacy (mDOR 17.3 mos, mOS 21.3 mos) and a manageable safety profile in pts with pretreated, ICI-naive HAC, a pt population with a high unmet need. Clinical trials of bintrafusp alfa in HAC are ongoing.
958O
Coordinated Activation of Antitumor Responses of g9d2 and CD8 T Cells by Targeting BTN3A with ICT01 in Patients with Solid Tumors: EVICTION Trial
A. Marabelle, et al.
Conclusions
ICT01-activated g9d2 T-cells orchestrate a broad antitumor immune response that supports cohort expansion.